These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17896835)

  • 21. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
    Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spatial dynamics of TRAIL death receptors in cancer cells.
    Twomey JD; Kim SR; Zhao L; Bozza WP; Zhang B
    Drug Resist Updat; 2015 Mar; 19():13-21. PubMed ID: 25840763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms.
    Reed JC
    Nat Clin Pract Oncol; 2006 Jul; 3(7):388-98. PubMed ID: 16826219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth control of normal and malignant lymphocytes--cell death research from basic concepts to signal pathways and translation into the clinic.
    Debatin KM
    Klin Padiatr; 2009; 221(6):332-8. PubMed ID: 19890783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation.
    Maas C; Verbrugge I; de Vries E; Savich G; van de Kooij LW; Tait SW; Borst J
    Cell Death Differ; 2010 Oct; 17(10):1613-23. PubMed ID: 20395960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
    Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
    Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
    Festuccia C; Gravina GL; D'Alessandro AM; Millimaggi D; Di Rocco C; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Int J Oncol; 2008 Aug; 33(2):381-8. PubMed ID: 18636160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
    Fulda S; Wick W; Weller M; Debatin KM
    Nat Med; 2002 Aug; 8(8):808-15. PubMed ID: 12118245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TRAIL and cancer therapy.
    Kruyt FA
    Cancer Lett; 2008 May; 263(1):14-25. PubMed ID: 18329793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.
    Mao HL; Liu PS; Zheng JF; Zhang PH; Zhou LG; Xin G; Liu C
    Pharmacol Res; 2007 Dec; 56(6):483-92. PubMed ID: 18029193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
    Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA
    Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.
    Goldsmith KC; Hogarty MD
    Cancer Lett; 2005 Oct; 228(1-2):133-41. PubMed ID: 15927359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRAILing death in cancer.
    Mellier G; Huang S; Shenoy K; Pervaiz S
    Mol Aspects Med; 2010 Feb; 31(1):93-112. PubMed ID: 19995571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Smac/DIABLO in cancer progression.
    Martinez-Ruiz G; Maldonado V; Ceballos-Cancino G; Grajeda JP; Melendez-Zajgla J
    J Exp Clin Cancer Res; 2008 Sep; 27(1):48. PubMed ID: 18822137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
    Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
    Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploiting apoptosis pathways for the treatment of pediatric cancers.
    Fulda S
    Pediatr Blood Cancer; 2009 Oct; 53(4):533-6. PubMed ID: 19148945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitor of apoptosis proteins in hematological malignancies.
    Fulda S
    Leukemia; 2009 Mar; 23(3):467-76. PubMed ID: 19039324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.